Pfizer Inc. (PFE)

Over the past six months, Pfizer's stock price has declined by 7.29%, and over the last year, it has decreased by 18.19%. As of July 18, 2025, the share price was $24.47, a 17.33% decline from July 22, 2024. Recent events include a corporate restructuring to cut over $7 billion in spending by 2027 due to declining COVID-19 vaccine demand. In May 2025, the stock gained after Pfizer announced it would license an experimental cancer drug for up to $6 billion. Analyst price targets range from $24.0 to $33.0, with a median of $26.5. Congressional members have traded PFE stock 17 times in the past six months, with 7 purchases and 10 sales. Insider trading activity in the same period shows 1 purchase and 1 sale.

Demand seasonality for Pfizer's products is evident, particularly for Comirnaty and Paxlovid. The company anticipates a seasonal cadence for certain products, with second-quarter 2024 Comirnaty revenues declining due to lower demand. Paxlovid results are expected to trend with infection rates, indicating a seasonal pattern tied to COVID-19 prevalence. The FDA approval of its KP.2-adapted COVID-19 vaccine positions it for the 2024-2025 season.

Pfizer Inc. is a global biopharmaceutical company involved in researching, developing, manufacturing, marketing, selling, and distributing healthcare products. Its core business focuses on biopharmaceutical products for therapeutic areas like immunology, oncology, and neurology, as well as vaccines. Key products include Eliquis, Prevnar, Paxlovid, Vyndaqel, Comirnaty, and Ibrance, along with over-the-counter products like Advil and Centrum.

Pfizer Inc. operates in approximately 200 countries and territories, categorized into the United States, Developed Markets, and Emerging Markets. It has 37 manufacturing sites worldwide, including 11 in the U.S., with large facilities in Kalamazoo, Michigan, and Rocky Mount, North Carolina. The company adapts its business model to meet diverse regulatory and market needs.

Pfizer's brand reputation has been influenced by its navigation of the post-pandemic landscape and strategic corporate changes. The corporate restructuring in July 2025, including the departure of the chief corporate affairs officer, was a notable event. Pfizer has historically engaged in initiatives to improve its reputation, such as signing the U.N. Global Compact. Its strong market position and global reach, demonstrated during the COVID-19 pandemic, contribute to its reputation as a reliable pharmaceutical provider.

Pfizer Inc. is primarily owned by institutional shareholders, holding 64.30% of the stock, while retail investors own 35.44%, and insiders hold 0.27%. Vanguard Group Inc. is the largest shareholder, owning 9.20% of the company. Other significant institutional owners include BlackRock, Inc., and State Street Corp. Top individual shareholders include Albert Bourla, Mikael Dolsten, and Douglas Lankler.